Provided by Tiger Trade Technology Pte. Ltd.

Cabaletta Bio

2.69
+0.12014.67%
Volume:2.04M
Turnover:5.42M
Market Cap:258.96M
PE:-1.12
High:2.75
Open:2.60
Low:2.56
Close:2.57
52wk High:3.67
52wk Low:0.9857
Shares:96.27M
Float Shares:61.64M
Volume Ratio:1.77
T/O Rate:3.30%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4075
EPS(LYR):-2.3627
ROE:-101.06%
ROA:-51.82%
PB:1.86
PE(LYR):-1.14

Loading ...

Analysts Offer Insights on Healthcare Companies: Cabaletta Bio (CABA) and Ocular Therapeutix (OCUL)

TIPRANKS
·
Feb 05

Cabaletta Bio to Participate in Guggenheim Emerging Outlook Biotech Summit

Reuters
·
Feb 05

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Feb 03

Cabaletta Bio, Inc. (NASDAQ:CABA) institutional owners may be pleased with recent gains after 9.7% loss over the past year

Simply Wall St.
·
Jan 22

Cabaletta Bio Insiders Go on a Buying Spree, Signaling Strong Confidence From the Top

TIPRANKS
·
Jan 22

Cabaletta Bio CEO Steven Nichtberger Reports Acquisition of Common Shares

Reuters
·
Jan 22

Cabaletta Bio Director Mark Simon Reports Acquisition of Common Shares

Reuters
·
Jan 22

Cabaletta Bio announces 2026 strategic priorities

TIPRANKS
·
Jan 12

Cabaletta Bio Outlines 2026 Strategy Focused on Enrolling Pivotal Myositis Trial, Advancing Outpatient and No Preconditioning Rese-cel Therapies, and Scaling Automated Manufacturing for Autoimmune Disease Pipeline

Reuters
·
Jan 12

Press Release: Cabaletta Bio Announces 2026 Strategic Priorities

Dow Jones
·
Jan 12

FDA Clears IND Amendment for Cabaletta Bio’s Rese-cel Clinical Manufacturing

Reuters
·
Jan 12

Ind Amendment Clearance Obtained for Clinical Manufacturing of Rese-Cel From Cabaletta Bio Using Cellares' Automated Platforms

THOMSON REUTERS
·
Jan 12

Cabaletta Bio Unveils Plans for CD19 Cell Therapies Targeting Autoimmune Diseases

Reuters
·
Dec 07, 2025

Guggenheim Sticks to Its Buy Rating for Cabaletta Bio (CABA)

TIPRANKS
·
Nov 14, 2025

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Nov 12, 2025

Cabaletta Bio (CABA) Gets a Buy from H.C. Wainwright

TIPRANKS
·
Nov 11, 2025

Cabaletta Bio Advances in Autoimmune Therapy Development

TIPRANKS
·
Nov 11, 2025

Cabaletta Bio: Promising Clinical Progress and Strategic Advancements Drive Buy Rating

TIPRANKS
·
Nov 11, 2025

Cabaletta Bio reports smaller-than-expected Q3 loss

Reuters
·
Nov 10, 2025

Cabaletta Bio reports Q3 EPS (44c), consensus (46c)

TIPRANKS
·
Nov 10, 2025